550 related articles for article (PubMed ID: 19090867)
1. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR
Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867
[TBL] [Abstract][Full Text] [Related]
2. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
3. Time savings associated with C.E.R.A. once monthly: a time-and-motion study in hemodialysis centers in five European countries.
De Cock E; Dellanna F; Khellaf K; Klatko W; Maduell F; Raluy-Callado M; Villa G
J Med Econ; 2013; 16(5):648-56. PubMed ID: 23402559
[TBL] [Abstract][Full Text] [Related]
4. Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management.
Kanbay M; Perazella MA; Kasapoglu B; Koroglu M; Covic A
Blood Purif; 2010; 29(1):1-12. PubMed ID: 19816014
[TBL] [Abstract][Full Text] [Related]
5. Costs associated with erythropoiesis-stimulating agent administration to hemodialysis patients.
Churchill DN; Macarios D; Attard C; Kallich J; Goeree R
Nephron Clin Pract; 2007; 106(4):c193-8. PubMed ID: 17596729
[TBL] [Abstract][Full Text] [Related]
6. Less frequent dosing of erythropoiesis stimulating agents in patients undergoing dialysis: a European multicentre cost study.
Burnier M; Douchamps JA; Tanghe A; Demey J; Perrault L; Foster CE; Robbins S
J Med Econ; 2009 Jun; 12(2):77-86. PubMed ID: 19450138
[TBL] [Abstract][Full Text] [Related]
7. Meeting new challenges in the management of anemia of chronic kidney disease through collaborative care with pharmacists.
Bacchus S; O'Mara N; Manley H; Fishbane S
Ann Pharmacother; 2009 Nov; 43(11):1857-66. PubMed ID: 19826095
[TBL] [Abstract][Full Text] [Related]
8. Characterizing hospitalizations of end-stage renal disease patients on dialysis and inpatient utilization of erythropoiesis-stimulating agent therapy.
Brophy DF; Daniel G; Gitlin M; Mayne TJ
Ann Pharmacother; 2010 Jan; 44(1):43-9. PubMed ID: 20028955
[TBL] [Abstract][Full Text] [Related]
9. Bundled-rate legislation for Medicare reimbursement for dialysis services: implications for anemia management with ESAs.
Charytan C
Clin J Am Soc Nephrol; 2010 Dec; 5(12):2355-62. PubMed ID: 21071515
[TBL] [Abstract][Full Text] [Related]
10. Economic considerations in a changing anemia environment.
Pizzi LT
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S29-33. PubMed ID: 19010259
[TBL] [Abstract][Full Text] [Related]
11. Peginesatide: a potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure.
Doss S; Schiller B
Nephrol Nurs J; 2010; 37(6):617-26. PubMed ID: 21290916
[TBL] [Abstract][Full Text] [Related]
12. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations.
Collins AJ
Nephrol Dial Transplant; 2003 Jun; 18 Suppl 2():ii2-6. PubMed ID: 12819293
[TBL] [Abstract][Full Text] [Related]
13. [Cost minimisation analysis for darbepoetin alpha vs. epoetin alpha in chronic kidney disease patients on haemodialysis].
Cuesta Grueso C; Poveda Andrés JL; Garcia Pellicer J; Romá Sánchez E
Farm Hosp; 2010; 34(2):68-75. PubMed ID: 20206567
[TBL] [Abstract][Full Text] [Related]
14. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.
Duh MS; Mody SH; Scott McKenzie R; Lefebvre P; Gosselin A; Tak Piech C
Clin Ther; 2006 Sep; 28(9):1443-50. PubMed ID: 17062316
[TBL] [Abstract][Full Text] [Related]
15. An economic evaluation of erythropoiesis-stimulating agents in CKD.
Clement FM; Klarenbach S; Tonelli M; Wiebe N; Hemmelgarn B; Manns BJ
Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621
[TBL] [Abstract][Full Text] [Related]
16. Finding a rational approach to ESA therapy--for payers and patients.
Messana A
Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
[No Abstract] [Full Text] [Related]
17. Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease.
Lafeuille MH; Bailey RA; Vekeman F; Kilpatrick BS; Senbetta M; Piech CT; Lefebvre P
Consult Pharm; 2010 Aug; 25(8):493-500. PubMed ID: 20736158
[TBL] [Abstract][Full Text] [Related]
18. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
Singh AK
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
[TBL] [Abstract][Full Text] [Related]
19. Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective.
Gauthier-Loiselle M; Michalopoulos SN; Cloutier M; Serra E; Bungay R; Szabo E; Guérin A
J Manag Care Spec Pharm; 2021 Dec; 27(12):1703-1713. PubMed ID: 34818094
[No Abstract] [Full Text] [Related]
20. Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease.
Lefebvre P; Duh MS; Buteau S; Bookhart B; Mody SH
J Am Soc Nephrol; 2006 Dec; 17(12):3497-502. PubMed ID: 17082245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
